INTERPACE BIOSCIENCES, INC. Files 8-K
Ticker: IDXG · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1054102
| Field | Detail |
|---|---|
| Company | Interpace Biosciences, Inc. (IDXG) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
INTERPACE BIOSCIENCES filed an 8-K, likely containing routine updates.
AI Summary
On January 9, 2025, INTERPACE BIOSCIENCES, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that INTERPACE BIOSCIENCES, INC. has submitted a report to the SEC, which may contain important updates or disclosures for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification without specific material events, suggesting low immediate risk.
Key Players & Entities
- INTERPACE BIOSCIENCES, INC. (company) — Registrant
- January 9, 2025 (date) — Date of earliest event reported
- 20250109 (date) — Conformed period of report
- 20250110 (date) — Filing date
FAQ
What is the primary purpose of this 8-K filing?
The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering "Other Events" and "Financial Statements and Exhibits."
When was the earliest event reported in this filing?
The earliest event reported was on January 9, 2025.
What is the exact name of the company filing this report?
The exact name of the company is INTERPACE BIOSCIENCES, INC.
In which state was INTERPACE BIOSCIENCES, INC. incorporated?
The company was incorporated in Delaware.
What is the SEC file number for INTERPACE BIOSCIENCES, INC.?
The SEC file number is 000-24249.
Filing Stats: 513 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-01-10 16:10:32
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 20KB
- 0001493152-25-001699.txt ( ) — 258KB
- idxg-20250109.xsd (EX-101.SCH) — 3KB
- idxg-20250109_lab.xml (EX-101.LAB) — 33KB
- idxg-20250109_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2025 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) Waterview Plaza , Suite 310 2001 Route 46 , Parsippany , NJ 07054 (Address, including zip code, of Principal Executive Offices) (855) 776-6419 Registrant's telephone number, including area code Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered None N/A N/A Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01. Other Events. On January 9, 2025, Interpace Biosciences, Inc. (the "Company") issued a press release announcing that Interpace Diagnostics, LLC, a subsidiary of the Company, responded to the final Local Coverage Determination ("LCD") of Genetic Testing for Oncology (L39365) issued by the Centers for Medicare & Medicaid Services. The new LCD establishes non-coverage for the Company's PancraGEN test, a molecular diagnostic test that assesses pancreatic cyst cancer risk ("PancraGEN"). Because PancraGEN is primarily ordered for Medicare patients, the Company will no longer be offering its PancraGEN test. Specimens for first-line fluid chemistry and PancraGEN testing will not be accepted after February 7, 2025 as a result of the new LCD. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press Release dated January 9, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Interpace Biosciences, Inc. By: /s/ Thomas W. Burnell Name: Thomas W. Burnell Title: President and Chief Executive Officer Date: January 10, 2025